These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Culprit and victim -- DNA topoisomerase II. Kellner U; Sehested M; Jensen PB; Gieseler F; Rudolph P Lancet Oncol; 2002 Apr; 3(4):235-43. PubMed ID: 12067686 [TBL] [Abstract][Full Text] [Related]
4. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Sinha BK Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211 [TBL] [Abstract][Full Text] [Related]
5. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Houlbrook S; Addison CM; Davies SL; Carmichael J; Stratford IJ; Harris AL; Hickson ID Br J Cancer; 1995 Dec; 72(6):1454-61. PubMed ID: 8519659 [TBL] [Abstract][Full Text] [Related]
6. [Poisons of DNA topoisomerases I and II]. Charcosset JY; Soues S; Laval F Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034 [TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerases and topoisomerase inhibitors. Giaccone G Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789 [TBL] [Abstract][Full Text] [Related]
8. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S; De Jong S; De Vries EG; Mulder NH Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Beck WT; Danks MK Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118 [TBL] [Abstract][Full Text] [Related]
10. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. McLeod HL; Douglas F; Oates M; Symonds RP; Prakash D; van der Zee AG; Kaye SB; Brown R; Keith WN Int J Cancer; 1994 Dec; 59(5):607-11. PubMed ID: 7960233 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813 [TBL] [Abstract][Full Text] [Related]
12. Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. Skok Ž; Zidar N; Kikelj D; Ilaš J J Med Chem; 2020 Feb; 63(3):884-904. PubMed ID: 31592646 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to topoisomerases poisons. Prost S Gen Pharmacol; 1995 Dec; 26(8):1773-84. PubMed ID: 8745168 [TBL] [Abstract][Full Text] [Related]
14. Topoisomerases in human leukemia. Peereboom D; Charron M; Kaufmann SH Adv Pharmacol; 1994; 29B():33-50. PubMed ID: 8996600 [No Abstract] [Full Text] [Related]
15. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Giles GI; Sharma RP Med Chem; 2005 Jul; 1(4):383-94. PubMed ID: 16789895 [TBL] [Abstract][Full Text] [Related]
16. HER-2/neu and topoisomerase IIalpha in breast cancer. Järvinen TA; Liu ET Breast Cancer Res Treat; 2003 Apr; 78(3):299-311. PubMed ID: 12755489 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144 [TBL] [Abstract][Full Text] [Related]
18. Drugs acting on DNA topoisomerases: recent advances and future perspectives. Gatto B; Capranico G; Palumbo M Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890 [TBL] [Abstract][Full Text] [Related]
19. [Molecular determinants of response to topoisomerase II inhibitors]. Lansiaux A; Pourquier P Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806 [TBL] [Abstract][Full Text] [Related]